Subject: Participation in survey “Criteria for selection of newer hormonal agents as first line therapy for the management of metastatic castration sensitive prostate cancer & choice of androgen deprivation treatment for prostate cancer management”
Prostate cancer is primarily a disease of the elderly with more than three quarter of the cases occurring in men above 65 years of age. According to the GLOBOCAN 2022 estimates, 37948 new cases of prostate cancer were diagnosed in 2022 in India. Fortunately, most prostate cancers tend to grow slowly and are low-grade with relatively low risk and limited aggressiveness. There are no initial or early symptoms in most cases, but late symptoms may include fatigue due to anemia, bone pain, paralysis from spinal metastases, and renal failure from bilateral ureteral obstruction.
Prostate cancer is a hormone-dependent malignancy, whose onset and progression are closely related to the activity of the androgen receptor (AR) signaling pathway. Due to this critical role of AR signaling in driving prostate cancer, therapy targeting the AR pathway has been the mainstay strategy for metastatic prostate cancer treatment.
Treatment for localized prostate cancer encompasses active surveillance, ablative radiotherapy, and radical prostatectomy. Patients who relapse or present metastatic prostate cancer receive androgen deprivation therapy (ADT), salvage radiotherapy, chemotherapy and androgen receptor inhibitors (ARi).
Androgen deprivation therapy (ADT) is also known as hormonal therapy and it is given to suppress the testosterone production and controlling the tumor growth. Testosterone suppression is often achieved using bilateral orchiectomy or medical castration via administration of luteinizing hormone-releasing hormone (LHRH) agonist or antagonists.
The treatment of metastatic prostate cancer has changed significantly over the past decade with the emergence of novel androgen receptor inhibitors (ARi). At present, Abiraterone, enzalutamide, apalutamide and darolutamide are approved for the management of different stages of prostate cancer.
Employing novel AR inhibitors (ARi) as intensified upfront systemic treatment in metastatic prostate cancer have demonstrated substantial benefits in delaying disease progression and prolonging overall survival. Administration of novel ARi has become the new standard of care in metastatic prostate cancer.
There is limited data available on the preference and rationale for selection of first line therapy in the management of metastatic prostate cancer.
Therefore, this multicentric survey is designed to understand the management of metastatic prostate cancer and place of apalutamide in mCSPC management in India.
If you agree to participate, you will be required to respond to questions of the enclosed questionnaire. We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this survey. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})